Ebastine

RESPIRATORY SYSTEM

Also known as: bastel, ebastel, ebastin, erostin, kestine

YEAR INTRODUCED approvedATC R06AX22

Data last refreshed: 2026-11-07 (DrugCentral release 2024-11-01)

Open interactive profile (3D, safety, PGx)

Key facts

Ebastine is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1990. DrugCentral lists 38 molecular targets, including HRH1, HTR2A and PRKAA2. Recorded indications include Allergic rhinitis and Chronic idiopathic urticaria.

Molecular targets: HRH1, HTR2A, PRKAA2 and ADRA2C (38 listed in DrugCentral).
Indications: Allergic rhinitis and Chronic idiopathic urticaria.
ATC code: R06AX22 (Other antihistamines for systemic use).
Molecular formula: C32H39NO2; molecular weight 469.67 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

Allergic rhinitis
Chronic idiopathic urticaria

Mechanism & targets

Molecular targets (38)

Target	Gene	Action	Activity
Histamine H1 receptor	HRH1	antagonist	Ki 8.00
5-hydroxytryptamine receptor 2A	HTR2A	unknown	Ki 7.59
5'-AMP-activated protein kinase catalytic subunit alpha-2	PRKAA2	unknown	Ki 7.58
Alpha-2C adrenergic receptor	ADRA2C	unknown	Ki 7.40
D(3) dopamine receptor	DRD3	unknown	Ki 7.38
Histamine H1 receptor	HRH1	unknown	IC50 7.35
5-hydroxytryptamine receptor 1A	HTR1A	unknown	IC50 7.33
D(2) dopamine receptor	DRD2	unknown	IC50 7.21
Sodium-dependent dopamine transporter	SLC6A3	unknown	Ki 7.11
Muscarinic acetylcholine receptor M4	CHRM4	unknown	Ki 6.94
5-hydroxytryptamine receptor 2C	HTR2C	unknown	Ki 6.91
Muscarinic acetylcholine receptor M3	CHRM3	unknown	Ki 6.86
5-hydroxytryptamine receptor 2B	HTR2B	unknown	Ki 6.70
Alpha-1B adrenergic receptor	Adra1b	unknown	Ki 6.63
Muscarinic acetylcholine receptor M5	CHRM5	unknown	Ki 6.62
Muscarinic acetylcholine receptor M2	CHRM2	unknown	Ki 6.55
Potassium voltage-gated channel subfamily H member 2	KCNH2	unknown	IC50 6.55
Alpha-2A adrenergic receptor	ADRA2A	unknown	Ki 6.51
Alpha-2B adrenergic receptor	ADRA2B	unknown	Ki 6.47
D(4) dopamine receptor	DRD4	unknown	Ki 6.34

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1990-01-01	YEAR INTRODUCED	—	—

ATC classification

ATC code	Therapeutic hierarchy
`R06AX22`	RESPIRATORY SYSTEM › ANTIHISTAMINES FOR SYSTEMIC USE › ANTIHISTAMINES FOR SYSTEMIC USE › Other antihistamines for systemic use

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
COVID-19	244.6
Urticaria	146.9
Drug reaction with eosinophilia and systemic symptoms	124.8
Angioedema	111.9
Allergy test positive	84.6
Endocrine ophthalmopathy	83.1
Dental caries	76.5
Gallbladder polyp	74.5
Nasal ulcer	67.2
Toxic shock syndrome	65.9
Death	60.0
Eczema	57.2

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Ebastine is on its molecule page.

Molecular formula	C₃₂H₃₉NO₂
Molecular weight	469.67 g/mol
CAS number	—
InChIKey	MJJALKDDGIKVBE-UHFFFAOYSA-N
PubChem CID	3191

CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Ebastine used for?

DrugCentral lists the following indications for Ebastine: Allergic rhinitis and Chronic idiopathic urticaria.

How does Ebastine work?

Its molecular targets in DrugCentral include HRH1 (antagonist), HTR2A, PRKAA2 and ADRA2C.

When was Ebastine first approved?

Ebastine was first approved by the YEAR INTRODUCED in 1990.

What is the chemical formula of Ebastine?

Ebastine has the molecular formula C32H39NO2 and a molecular weight of 469.67 g/mol.

Browse: all drugs starting with E · drug guides by category · protein targets A–Z.

Sources

DrugCentral drug card 977 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
ChEMBL CHEMBL305660 — compound record and bioactivity
PubChem CID 3191 — chemical identifiers
DrugBank DB11742 — drug record
FDA UNII TQD7Q784P1 — substance identity
UniProt P35367 (HRH1) — target protein
UniProt P28223 (HTR2A) — target protein
UniProt P54646 (PRKAA2) — target protein
UniProt P18825 (ADRA2C) — target protein
UniProt P35462 (DRD3) — target protein
UniProt P08908 (HTR1A) — target protein
FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.